Current aspects of systematics, diagnosis and treatment of breast cancer-Reference-Cited by-同舟云学术

Current aspects of systematics, diagnosis and treatment of breast cancer

Published:2022-05-07 Issue:1 Volume:18 Page:25-39
ISSN:1999-8627
Container-title:Tumors of female reproductive system
language:
Short-container-title:Opuholi ženskoj reproduktivnoj sistemy

Author:

Strunkin D. N.¹^ORCID,Kononchuk V. V.²^ORCID,Gulyaeva L. F.³^ORCID,Bogachev S. S.⁴^ORCID,Proskurina A. S.⁴^ORCID

Affiliation:

1. Research Institute of Molecular Biology and Biophysics, Federal Research Center for Fundamental and Translational Medicine; Research Institute of Fundamental and Clinical Immunology

2. Research Institute of Molecular Biology and Biophysics, Federal Research Center for Fundamental and Translational Medicine; Research Institute of Clinical and Experimental Lymphology, a branch of the Federal Research Center, Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences

3. Research Institute of Molecular Biology and Biophysics, Federal Research Center for Fundamental and Translational Medicine

4. Federal Research Center, Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences

Abstract

The purpose of the study was to mine, compile and analyze the published data on breast cancer (BC) systematization, diagnosis and treatment. In the current review, modern approaches in BC subtypes diagnosis based on genomic profiling, miRNA expression pattern analysis, SNP analysis in BRCA1 and BRCA2 genes, as well as proteomic mapping as essential components of the disease peculiarities improving the prognostic outcome were compiled and analyzed. Further, tumor-initiating stem-like cells as a factor affecting both prognosis and treatment choice for BC are considered and evaluated. And finally, modern principles of enhancing tumor sensitivity to therapeutic effects of anticancer drugs, which comprise the use of cytostatics in condensed modes, combining drugs, which exert different mechanisms of cytotoxicity, as well as the introduction of new chemotherapy drugs into therapeutic practice, including those targeted against the common metabolic pathways both in stem-like and committed breast cancer cells, are compiled and discussed. The analysis indicates that the current paradigm in BC treatment is development and implementation of the newest methods for diagnosis of BC sybtypes, which, being combined with those already implemented, would allow the administration of treatment according to the individual peculiarities of a tumor.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference97 articles.

1. Ferlay J., Colombet M., Soerjomataram I. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356–87. DOI: 10.1016/j.ejca.2018.07.005.

2. Stewart B.W., Wild C. International Agency for Research on Cancer, World Health Organization. World Cancer Rep 2014.

3. Cheng Y.C., Ueno N.T. Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer2012;19:191–9. DOI: 10.1007/s12282-011-0276-3.

4. Mackey J.R., Martin M., Pienkowski T. et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013;14:72–80. DOI: 10.1016/S1470-2045(12)70525-9.

5. Kuraparthy S., Reddy K.M., Yadagiri L.A. et al. Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol 2007;5:56. DOI: 10.1186/1477-7819-5-56.